R1 Therapeutics Launches with $77.5 Million, Unveiling Novel Oral Treatment for Chronic Kidney Disease Complication
admin Redwood City, California – March 17, 2026 – In a significant move set to potentially...
biotech
Bridging the Therapeutic Divide: Advancing Immunotherapy for Advanced Cervical Cancer Through Innovative Research
The global health community has lauded the remarkable progress in cervical cancer prevention, largely attributable...
Structure Therapeutics’ Aleniglipron Shows “Injectable-Like Efficacy” in Promising Phase 2 Obesity Trial, Intensifying Oral GLP-1 Race
Structure Therapeutics, a rapidly emerging biotech firm, has announced compelling Phase 2 trial results for...
CytomX surges on positive data for ‘masked’ ADC in colorectal cancer
CytomX Therapeutics, a biopharmaceutical company focused on developing novel cancer therapies, announced on March 16,...
February: A Critical Look at Preventable Cancers and Proactive Health Strategies
February marks National Cancer Prevention Month, a dedicated period for the United States to underscore...
FDA Revolutionizes Product Safety Monitoring with Unified Surveillance Dashboard, Consolidating Disparate Systems for Enhanced Utility and Efficiency
The U.S. Food and Drug Administration (FDA) has announced a significant overhaul of its product...
A Beacon of Hope: How Immunotherapy Transformed the Battle Against Rare Ampullary Cancer for Adrienne Skinner
Adrienne Skinner’s journey from a grim prognosis of rare, stage 4 ampullary cancer to a...
Eli Lilly Urges FDA to Recall Compounded Zepbound, Citing "Dangerous" Impurities and "Unknown Risks" in Unauthorized Formulations
Eli Lilly has intensified its campaign against compounded versions of its blockbuster obesity drug Zepbound...
FDA Streamlines Biosimilar Approval Pathway to Boost Competition and Lower Drug Costs
The U.S. Food and Drug Administration (FDA) has announced significant draft guidance aimed at accelerating...
Cancer in 2026: How Immunotherapy Is Reshaping the Odds
The American Cancer Society’s (ACS) highly anticipated Cancer Statistics 2026 report paints a compelling picture...
